Stocks and Investing
Stocks and Investing
Wed, January 5, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, January 4, 2022
[ 12:00 AM ] - WOPRAI
Elemer Piros Upgraded (UBX) to Strong Buy and Held Target at $40 on, Jan 4th, 2022
Elemer Piros of Roth Capital, Upgraded "Unity Biotechnology, Inc." (UBX) to Strong Buy and Held Target at $40 on, Jan 4th, 2022.
Elemer has made no other calls on UBX in the last 4 months.
There is 1 other peer that has a rating on UBX. Out of the 1 peers that are also analyzing UBX, 0 agree with Elemer's Rating of Hold.
This is the rating of the analyst that currently disagrees with Elemer
- Salim Syed of "Mizuho" Upgraded from Hold to Strong Buy and Increased Target to $70 on, Wednesday, November 10th, 2021
Contributing Sources